Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa J Deesker

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|March 13, 2024
Lumasiran, Isolated Kidney Transplantation, and Continued VigilanceJustine Bacchetta, Stéphanie Clavé, Peggy Perrin, et al.
Journal of Inherited Metabolic Disease|November 24, 2024
Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluriaRonald J A Wanders, Jaap W Groothoff, Lisa J Deesker, et al.
Pediatric Nephrology (Berlin, Germany)|January 4, 2023
Weight loss and metabolic acidosis in a neonate: QuestionsLisa J Deesker, Michiel J S Oosterveld, Marije J van Mill, et al.
Pediatric Nephrology (Berlin, Germany)|January 4, 2023
Weight loss and metabolic acidosis in a neonate: AnswersLisa J Deesker, Michiel J S Oosterveld, Marije J van Mill, et al.
Kidney International|October 20, 2023
Corrigendum to "Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy." Kidney International, 2023;104:203-204Elisabeth L Metry, Lisa J Deesker, Sander F Garrelfs, et al.
Orphanet Journal of Rare Diseases|December 24, 2024
Application of four pricing models for orphan medicines: a case study for lumasiranNoa Rosenberg, Evert Manders, Sibren van den Berg, et al.
Kidney International|June 22, 2023
Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapyElisabeth L Metry, Lisa J Deesker, Sander F Garrelfs, et al.
The Lancet Regional Health. Europe|April 14, 2025
New opportunities for accessing promising non-oncological orphan drugsCarla E M Hollak, Carelle C Reparon-Schuijt, Kathelijn Verdeyen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 22, 2025
Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in The NetherlandsLisa J Deesker, Casper F M Franssen, Eiske Dorresteijn, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 21, 2025
Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K working group of the ERA, and ESPNLisa J Deesker, Laila Oubram, Reham Almardini, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|March 13, 2024
Lumasiran, Isolated Kidney Transplantation, and Continued VigilanceJustine Bacchetta, Stéphanie Clavé, Peggy Perrin, et al.
Journal of Inherited Metabolic Disease|November 24, 2024
Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluriaRonald J A Wanders, Jaap W Groothoff, Lisa J Deesker, et al.
Pediatric Nephrology (Berlin, Germany)|January 4, 2023
Weight loss and metabolic acidosis in a neonate: QuestionsLisa J Deesker, Michiel J S Oosterveld, Marije J van Mill, et al.
Pediatric Nephrology (Berlin, Germany)|January 4, 2023
Weight loss and metabolic acidosis in a neonate: AnswersLisa J Deesker, Michiel J S Oosterveld, Marije J van Mill, et al.
Kidney International|October 20, 2023
Corrigendum to "Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy." Kidney International, 2023;104:203-204Elisabeth L Metry, Lisa J Deesker, Sander F Garrelfs, et al.
Orphanet Journal of Rare Diseases|December 24, 2024
Application of four pricing models for orphan medicines: a case study for lumasiranNoa Rosenberg, Evert Manders, Sibren van den Berg, et al.
Kidney International|June 22, 2023
Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapyElisabeth L Metry, Lisa J Deesker, Sander F Garrelfs, et al.
The Lancet Regional Health. Europe|April 14, 2025
New opportunities for accessing promising non-oncological orphan drugsCarla E M Hollak, Carelle C Reparon-Schuijt, Kathelijn Verdeyen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 22, 2025
Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in The NetherlandsLisa J Deesker, Casper F M Franssen, Eiske Dorresteijn, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 21, 2025
Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K working group of the ERA, and ESPNLisa J Deesker, Laila Oubram, Reham Almardini, et al.
Pageof 2